CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
GOG-0241 GOG A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Adult CIRB - Late Phase Emphasis
GOG-0249 GOG A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk; Early Stage Endometrial Carcinoma Adult CIRB - Late Phase Emphasis
GOG-0250 GOG A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297 Adult CIRB - Late Phase Emphasis
GOG-0252 GOG A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian; Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865; IND #113912) Adult CIRB - Late Phase Emphasis
GOG-0258 GOG A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked; Advanced Endometrial Carcinoma Adult CIRB - Late Phase Emphasis
GOG-0261 GOG A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV; Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus; Fallopian Tube; Peritoneum or Ovary Adult CIRB - Late Phase Emphasis
GOG-0262 GOG GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865; IND #113912) in the Treatment of Primary Stage II; III OR IV Epithelial Ovarian; Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262 Adult CIRB - Late Phase Emphasis
GOG-0263 GOG Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk; Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Adult CIRB - Late Phase Emphasis
GOG-0275 GOG A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia Adult CIRB - Late Phase Emphasis
GOG-0277 GOG A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NCS# 123127) versus Observation for Uterus-Limited; High Grade Uterine Leiomyosarcoma Adult CIRB - Late Phase Emphasis